Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model

2020309 citationsJournal Articlegold Open Access

Authors

Huahao Fan · Beijing University of Chemical Technology

Li-Qin Wang · Beijing University of Chemical Technology

Wen-Li Liu · Beijing University of Chemical Technology

Xiao-Ping An · Artvin Coruh University

Zhen-Dong Liu · Beijing University of Chemical Technology

Xiao-Qi He · Artvin Coruh University

Li-Hua Song

Abstract

Our pangolin coronavirus GX_P2V is a workable model for 2019-nCoV research. CEP, selamectin, and mefloquine hydrochloride are potential drugs for treating 2019-nCoV infection. Our results strongly suggest that CEP is a wide-spectrum inhibitor of pan-betacoronavirus, and further study of CEP for treatment of 2019-nCoV infection is warranted.

Topics & Keywords

SARS-CoV-2 and COVID-19 Research COVID-19 Clinical Research Studies PARP inhibition in cancer therapy

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Chinese Medical Journal

Volume 133, Issue 9, pp. 1051-1056

DOI: 10.1097/cm9.0000000000000797

Field-Weighted Citation Impact: 6.75

Command Palette